Prevalence of Chronic Kidney Disease in Patients with Pulmonary Arterial Hypertension.

2009 ◽  
Author(s):  
JC Cedergreen ◽  
CJ Markin ◽  
IM Wahba
Keyword(s):  
Chronic Kidney Disease ◽  
Pulmonary Arterial Hypertension ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Pulmonary Arterial

scholarly journals CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Klaudia Gieszczyk-Strózik ◽  
Maciej T. Wybraniec ◽  
Małgorzata Widuchowska ◽  
Ligia Brzezińska-Wcisło ◽  
Przemysław Kotyla ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Systemic Sclerosis ◽  
Pulmonary Arterial Hypertension ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Maximal Velocity ◽  
Pulmonary Arterial

AbstractThe aim of the study was to assess the predictors of major adverse cardiovascular events (MACE) in patients with systemic sclerosis (SSc) without pulmonary arterial hypertension. The study comprised 68 patients with SSc who were followed up for the median time of 99 (96; 107) months. The main exclusion criteria involved tricuspid regurgitation maximal velocity > 2.8 m/s and structural heart disease. At baseline the patients underwent clinical assessment of cardiovascular risk factors, 6-min walk test, transthoracic echocardiography and biomarker testing, including growth differentiation factor 15 (GDF-15). The primary composite endpoint was onset of MACE defined as death, myocardial infarction, myocardial revascularization and hospitalization for heart failure. The follow-up consisted of outpatient visits at 1 year intervals and telephone interview every 6 months. The baseline analysis revealed that chronic kidney disease (HR 28.13, 95%CI 4.84–163.38), lung fibrosis on high resolution computed tomography (HR 4.36, 95%CI 1.04–18.26) and GDF-15 concentration (unit HR 1.0006, 95%CI 1.0002–1.0010) were independent predictors of MACE occurrence. CHLD (Chronic kidney disease, Hypertension, hyperLipidaemia, Diabetes mellitus) score was formulated which assigned 1 point for the presence of arterial hypertension, hyperlipidaemia, diabetes mellitus and chronic kidney disease. After inclusion of CHLD score in Cox proportional model, it remained the only independent predictor of MACE onset (unit HR per 1 point 3.46; 95%CI 2.06–5.82, p < 0.0001). Joint assessment of traditional risk factors in the form of CHLD score may serve as a reliable predictor of long-term outcome in patients with SSc without pulmonary arterial hypertension.

scholarly journals A Hospital Based Study of Pulmonary Arterial Hypertension in Various Stages of Chronic Kidney Disease and Associated Risk Factors among Patients Attending a Tertiary Care Hospital in Ujjain, Madhya Pradesh

2021 ◽  
Vol 8 (20) ◽  
pp. 1500-1504
Author(s):  
Rajesh Deshpande ◽  
Amit Kumar Yadav ◽  
Vipin Porwal
Keyword(s):  
Chronic Kidney Disease ◽  
Pulmonary Arterial Hypertension ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Corticomedullary Differentiation ◽  
Pulmonary Arterial

BACKGROUND Multiple mechanisms have been identified contributing to pulmonary arterial hypertension (PAH) in chronic kidney disease (CKD) patients and it is one of the important sequelae of CKD and needs early detection. We wanted to study PAH in various stages of CKD and its association with renal and cardiovascular parameters. METHODS This was an observational study. PAH was diagnosed if mean pulmonary artery pressure (MPAP) was ≥ 25 mmHg using 2D - Doppler echocardiography in 96 CKD patients. Staging of CKD was done as per Kidney Disease Improving Global Outcomes (KDIGO) stages 1 - 5. Age, gender, diabetes, hypertension, stages of CKD, corticomedullary differentiation (CMD), estimated glomerular filtration rate (EGFR), urinary albumin creatinine ratio (UACR), left ventricular ejection fraction (LVEF) and left ventricular hypertrophy (LVH) were included as risk factors. Data was analysed by calculating percentage, mean, standard deviation, chi square and t test. P value < 0.05 was taken as statistically significant. RESULTS PAH was detected in 37 (38.5 %) of CKD patients. Prevalence of PAH increased with stages of CKD being highest (59 %) in stage 5 and this was found to be statistically significant (P = 0.04). PAH was detected earliest in stage 2 (23.5 %). Lower mean eGFR ml / min / 1.733m2 (24.43 ± 17.8 vs 40.98 ± 25.7, P = 0.001) altered corticomedullary differentiation (50.9 % vs 20.5 % p = 0.003), reduced LVEF (81 % vs 26.7 % P = 0.000) and LVH (65 % vs 19.6 %, P = 0.000) were significantly associated with PAH in CKD patients. CONCLUSIONS PAH in CKD patients increases with CKD stages. Onset of PAH in CKD patients may be earlier and significantly associated with left ventricular dysfunction. KEYWORDS Pulmonary Arterial Hypertension, Chronic Kidney Disease, Left Ventricular Ejection Fraction, Left Ventricular Hypertrophy

Determinants and prognostic value of kidney disease in pulmonary arterial hypertension

2018 ◽  
Author(s):  
Vincent Cottin ◽  
Laurent Bitker ◽  
Florence Sens ◽  
Cecile Payet ◽  
Ségolène Turquier ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Prognostic Value ◽  
Pulmonary Arterial

scholarly journals Endothelin Receptor Antagonists (ERA) in Hypertension and Chronic Kidney Disease: a Rose with Many Thorns

2013 ◽  
Vol 5 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Doumas M ◽  
Athyros V ◽  
Katsiki N ◽  
Reklou A ◽  
Lazaridis A ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Digital Ulcers ◽  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
Water Reabsorption ◽  
Receptor Antagonists ◽  
Pulmonary Arterial

The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the treatment of arterial hypertension. Endothelin plays a significant role in blood pressure regulation through pronounced vasoconstriction and modulation of sodium and water reabsorption in the kidneys. Endothelin receptor antagonists have been tested in many clinical trials in patients with arterial hypertension, heart failure, pulmonary arterial hypertension, systemic sclerosis, chronic kidney disease, and diabetic nephropathy. However, the results were usually disappointing, except in pulmonary hypertension and scleroderma digital ulcers. The future of ERAs for the treatment of arterial hypertension and chronic kidney disease does not seem bright, and only the combination with other classes of antihypertensive drugs might offer a way out.

732 Responsiveness to inhaled nitric oxide in patients with pulmonary arterial hypertension and right heart failure

2006 ◽  
Vol 5 (1) ◽  
pp. 171-171
Author(s):  
P PODOLEC ◽  
M KAZNICAWIATR ◽  
M HLAWATY ◽  
P WILKOLEK ◽  
Z PODOLEC ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Heart Failure ◽  
Inhaled Nitric Oxide ◽  
Right Heart ◽  
Pulmonary Arterial

123 Prevalence of pulmonary arterial hypertension and echocardiographic signs of right heart failure in HIV infected patients

2007 ◽  
Vol 6 (1) ◽  
pp. 30-30
Author(s):  
C BUHR ◽  
N REINSCH ◽  
P KRINGS ◽  
H KAELSCH ◽  
T KONORZA ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Heart Failure ◽  
Right Heart ◽  
Pulmonary Arterial

FDA: No to Revatio for Kids With Pulmonary Arterial Hypertension

2012 ◽  
Vol 42 (16) ◽  
pp. 10
Author(s):  
Frances Correa
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document